Vericel Corporation is a biopharmaceutical company focused on the development and commercialization of innovative cellular therapies for patients with severe diseases and conditions. The company's primary purpose is to provide next-generation solutions that harness the power of a patient's own cells to repair damaged tissues and restore function. Vericel specializes in treatments for sports medicine and severe burn care, with key products including MACI, a personalized autologous cellularized scaffold for knee cartilage repair, and Epicel, a permanent skin replacement for patients with extensive burn injuries. Vericel's products serve critical roles in the biotechnology and healthcare sectors, impacting clinical outcomes for patients experiencing serious musculoskeletal and skin injuries. With headquarters in Cambridge, Massachusetts, Vericel operates at the intersection of medical innovation and patient-focused care, contributing to advancements in cellular therapy technologies. Through collaborations with medical professionals and institutions, Vericel plays a significant role in enhancing the quality of life for individuals undergoing complex surgical procedures, leading the advancement of regenerative medicine by refining techniques to produce effective treatments with the potential to transform standard practices in patient care.